Clinical Trial

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open-label, randomized clinical trial aimed at exploring the efficacy and safety of three treatment regimens for treatment-naive advanced NSCLC patients with KRAS G12D mutation: GFH375 monotherapy (Cohort 1), GFH375 combined with cetuximab (Cohort 2), and GFH375 combined with pemetrexed (Cohort 3).Every cohort will recruit 30 participants.
Trial Details
NCT Number NCT07554859
Lead Sponsor Genfleet Therapeutics (Shanghai) Inc.
Conditions NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment 90 participants
Start Date 2026-05-20
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-28